|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CLINICAL STUDY |
A Colao, Molecular and Clinical Endocrinology and Oncology, University Federico II of Naples, Naples, 80131, Italy
C Di Somma, Molecular and Clinical Endocrinology and Oncology, University Federico II of Naples, Naples, Italy
T Cascella, Molecular and Clinical Endocrinology and Oncology, University Federico II of Naples, Naples, Italy
R Pivonello, Molecular and Clinical Endocrinology and Oncology, University Federico II of Naples, Naples, Italy
G Vitale, Milan, Italy
L Grasso, Molecular and Clinical Endocrinology and Oncology, University Federico II of Naples, Naples, Italy
G Lombardi, Molecular and Clinical Endocrinology and Oncology, University Federico II of Naples, Naples, Italy
S Savastano, Molecular and Clinical Endocrinology and Oncology, University Federico II of Naples, Naples, Italy
Correspondence: Annamaria Colao, Email: colao{at}unina.it
Abstract
Background: In the general population, low IGF-I has been associated with higher prevalence of cardiovascular disease and mortality.
Objective: To investigate the relationships between IGF-I levels, blood pressure (BP) and glucose tolerance (GT).
Subjects: 404 subjects (200 men 18-80 yrs aged). Exclusion criteria: personal history of pituitary or cardiovascular diseases; previous or current treatments with drugs interfering with BP, GT, or lipids, corticosteroids (>2 weeks), estrogens or testosterone (>12 weeks); smoking of >15 cigarettes/day and alcohol abuse (>3 glasses of wine/day).
Results: 296 had normal BP (73.3%), 86 had mild (21.3) and 22 had severe hypertension (5.4%); 322 had normal GT [NGT (79.7%)], 53 had impaired fasting glucose [IGT (13.1%)], 29 had diabetes mellitus (7.2%). Normotensive subjects had significantly higher IGF-I levels (0.11±0.94 SDS) than those with mild (-0.62±1.16 SDS, p<0.0001) or severe hypertension (-1.01±1.07 SDS, p<0.0001). IGF-I SDS (t=-3.41, p=0.001) independently predicted systolic and diastolic BP (t=-2.77, p=0.006). NGT subjects had significantly higher IGF-I levels (0.13±0.90 SDS) than those with IGT (-0.86±1.14 SDS, p<0.0001) or diabetes mellitus (-1.31±1.13 SDS, p<0.0001). IGF-I SDS independently predicted fasting glucose (t=-3.49, p=0.0005) and HOMA-R (t=-2.15, p=0.033) but not insulin (t=-1.92, p=0.055) and HOMA-β (t=-0.19, p=0.85).
Conclusion: IGF-I levels in the low normal range is associated with hypertension and diabetes in subjects without pituitary and cardiovascular diseases.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |